CD Genomics Unveils Advanced Mitochondrial Diseases Panel Sequencing Service
CD Genomics, a leading biotechnology company specializing in genomics and sequencing, has announced the launch of its advanced Mitochondrial Diseases Panel Sequencing services. This new panel enables rapid and accurate detection of mutations in mitochondrial DNA (mtDNA) that are associated with a wide range of mitochondrial disorders.
Mitochondrial diseases are a complex and heterogeneous group of disorders caused by mutations in mitochondrial DNA (mtDNA) or nuclear genes that encode proteins involved in mitochondrial function. The symptoms of these disorders can vary widely and may include muscle weakness, neurodegenerative disorders, vision and hearing loss, and metabolic disorders. However, detecting mitochondrial diseases can be challenging, as the symptoms are often nonspecific and can overlap with those of other conditions.
To address this challenge, CD Genomics has developed a comprehensive Mitochondrial Diseases Panel Sequencing service that enables researchers to accurately identify mitochondrial DNA and nuclear DNA mutations and obtain a comprehensive view of the patient’s genetic makeup. The panel includes over 200 genes associated with mitochondrial function and metabolism, covering both mtDNA and nuclear DNA mutations.
The Mitochondrial Diseases Panel Sequencing service is validated for high accuracy, sensitivity, and specificity, ensuring reliable results. The analysis is performed using state-of-the-art sequencing technologies, including Illumina PE150 and Illumina MiSeq, and is supported by CD Genomics’ team of experienced scientists and bioinformaticians.
“We are excited to launch our comprehensive Mitochondrial Diseases Panel Sequencing service for research use only, which provides a powerful tool for researchers to identify genetic mutations associated with mitochondrial diseases,” said the chief scientist at CD Genomics. “Our panel includes a broad range of genes related to mitochondrial function and metabolism, enabling researchers to obtain a comprehensive view of the patient’s genetic makeup and develop new insights into the underlying genetic causes of these diseases.”
In addition to the standard panel, CD Genomics also offers custom Mitochondrial Diseases Panel Service, allowing researchers to tailor the panel to their specific research needs. Customers can choose from a variety of options, including specific genes or regions of interest, sample types, and coverage depth.
CD Genomics is committed to providing high-quality genomics services to researchers worldwide. With the launch of its comprehensive Mitochondrial Diseases Panel Sequencing service for research use only, the company is poised to make a significant contribution to the understanding of mitochondrial diseases.
About CD Genomics
CD Genomics offers predesigned NGS panels, which include a designed library of targeted sequencings well as a custom panel that allows customers to select genes of interest and customize individual sequencing panels.
Address: Shirley, NY 11967, USA
- CD Genomics
- Dianna Gellar